Acute Diverticulitis and C-Reactive Protein as a Prognostic Marker

This study is not yet open for participant recruitment.
Verified April 2013 by Corporacion Parc Tauli
Sponsor:
Information provided by (Responsible Party):
LAURA MORA LOPEZ, Corporacion Parc Tauli
ClinicalTrials.gov Identifier:
NCT01825967
First received: March 29, 2013
Last updated: April 9, 2013
Last verified: April 2013
  Purpose

The management of acute diverticulitis maybe better if we have prognostic markers of evolution.

Hypothesis: C-reactive protein maybe a good prognostic marker of evolution of acute diverticulitis.

The investigators need to know the values of C-reactive protein to predict evolution of acute diverticulitis.


Condition Intervention
Acute Diverticulitis
Other: C-reactive protein

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Target Follow-Up Duration: 30 Days
Official Title: Predictive Value of C-Reactive Protein in Acute Diverticulitis

Resource links provided by NLM:


Further study details as provided by Corporacion Parc Tauli:

Primary Outcome Measures:
  • C-Reactive Protein [ Time Frame: 24 Hours ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 30
Study Start Date: April 2013
Estimated Study Completion Date: April 2014
Estimated Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Acute Diverticulitis
We measured C-reactive protein in all the patients diagnosed with acute diverticulitis
Other: C-reactive protein
measured C-reactive protein in all patients with acute diverticulitis

Detailed Description:

A prospective observational study. All the patients with TC-diagnosis of acute diverticulitis (AD) had a C-reactive protein (PCR) in the initial blood test.

The investigators will predict evolution of AD with the PCR initial.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

All Patients with Acute Diverticulitis

Criteria

Inclusion Criteria:

  • Acute Diverticulitis

Exclusion Criteria:

  • Other Abdominal Pathologies
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01825967

Contacts
Contact: MORA L. LAURA, MD 34639101033 Lmora@tauli.cat

Locations
Spain
Corporacion Parc Tauli Not yet recruiting
Sabadell, Barcelona, Spain, 08208
Contact    34937231010 ext 21490    Lmora@tauli.cat   
Contact: Laura Mora    3493723101033 ext 21490    Lmora@tauli.cat   
Corporacion parc tauli Not yet recruiting
Sabadell, Sabadell-Barcelona, Spain, 08208
Contact: MORA L. LAURA, MD    34639101033    Lmora@tauli.cat   
Principal Investigator: MORA L. LAURA, MD         
Corporacion Parc Tauli Not yet recruiting
Sabadell, Sabadell/barcelona, Spain, 08208
Contact: MORA L. LAURA, MD    34639101033    Lmora@tauli.cat   
Corporacion Parc Tauli
Sabadell, Sabadell/barcelona, Spain, 08208
Sponsors and Collaborators
Corporacion Parc Tauli
Investigators
Principal Investigator: MORA LAURA, MD Corporacion Parc Tauli
  More Information

No publications provided

Responsible Party: LAURA MORA LOPEZ, General Surgeon, Corporacion Parc Tauli
ClinicalTrials.gov Identifier: NCT01825967     History of Changes
Other Study ID Numbers: 2013/532
Study First Received: March 29, 2013
Last Updated: April 9, 2013
Health Authority: Spain: Ethics Committee

Additional relevant MeSH terms:
Diverticulitis
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on April 17, 2014